Improvement of the clinical applicability of tissue-engineered vascular grafts, as new regenerative therapy for children with congenital cardiovascular malformations

Projektinformationen

LIVAGRAFT

ID Finanzhilfevereinbarung: 626976

Abgeschlossenes Projekt

Startdatum 1 März 2014

Enddatum 29 Februar 2016

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 199 317,60

EU-Beitrag € 199 317,60

Koordiniert durch

University of Zurich
Switzerland

Ziel

Currently available artificial graft prostheses for congenital disorders lack the capacity of growth and often require complex and reconstructive surgical interventions. As a consequence, repetitive and high-risk surgical interventions during childhood are inescapable, associated with increased morbidity and mortality. This not only raises enormous costs for the society, but compromises the quality of life of the young patients. Therefore, manufacturing Living Vascular Grafts is the ultimate goal for both cardiovascular researchers and clinicians. Tissue engineering is an opportunity to create prostheses that are vital, growing, adaptive, and autologous and show optimal functionality. Such in-vitro tissue-engineered vascular grafts have demonstrated functionality and growth as pulmonary replacement in lambs. However, classical tissue engineering using autologous cells, necessitates invasive cell harvesting from the patient, time consuming cell expansion and production of the patient-specific graft. As the living cellular component of the grafts inherently limits clinical applicability, an accelular equivalent with corresponding strength, growth, and regenerative capacity, would provide an attractive alternative for the living tissue-engineered vascular grafts. Therefore, my goal is to improve the clinical applicability of the tissue-engineered pulmonary grafts by decellularizing them, therewith creating novel off-the-shelf constructs for children with congenital cardiovascular malformations. The in-vivo recellularization capacity of these accelular tissue-engineered pulmonary grafts will be evaluated in a pre-clinical animal model to demonstrate their potential to grow with the recipient. These innovative alterations to create unlimited off-the-shelf grafts will speed up the clinical translation of this novel concept. It will inherently favor the wellbeing of patients by reducing waiting time and avoiding reoperations, in addition to a reduction in health costs.

Wissenschaftliches Gebiet

• social sciences › sociology › demography › mortality
• medical and health sciences › medical biotechnology › tissue engineering
• medical and health sciences › clinical medicine › surgery › surgical procedures
• medical and health sciences › medical biotechnology › implants

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2013-IEF - Marie-Curie Action: "Intra-European fellowships for career development"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2013-IEF
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IEF - Intra-European Fellowships (IEF)

Koordinator

University of Zurich

Kontakt Verwaltung

Simon P. Hoerstrup (Prof.)

• EU-Beitrag: € 199 317,60
• Adresse: RAMISTRASSE 71 ; 8006 ZURICH ; Schweiz
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten